Acta NaturaeActa NaturaeActa Naturae2075-8251Acta Naturae Ltd1078110.32607/20758251-2009-1-3-84-88ArticlesСтатьиResearch ArticleProtein Tyrosine Kinase Panel As a Tool for Anticancer Drug DesignProtein Tyrosine Kinase Panel As a Tool for Anticancer Drug DesignRakitinaT Vtaniarakitina@yahoo.comYudkinaO VSmirnovaE VLipkinA VShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of SciencesA.N. Bakh Institute of Biochemistry, Russian Academy of SciencesInstitute of Crystallography, Russian Academy of SciencesRussian Research Center Kurchatov InstituteShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of SciencesInstitute of Crystallography, Russian Academy of SciencesRussian Research Center Kurchatov Institute1512200913NO3 (2009)№3 (2009)848817012020Copyright ©; 2009, Rakitina T.V., Yudkina O.V., Smirnova E.V., Lipkin A.V.Copyright ©; 2009, Rakitina T.V., Yudkina O.V., Smirnova E.V., Lipkin A.V.2009Rakitina T.V., Yudkina O.V., Smirnova E.V., Lipkin A.V.Rakitina T.V., Yudkina O.V., Smirnova E.V., Lipkin A.V.https://creativecommons.org/licenses/by/4.0https://actanaturae.ru/2075-8251/article/view/10781

The discovery of the pharmaceutical potential of small molecule inhibitors of oncogenic protein tyrosine kinases is one of the directions in target therapy in oncology. Presently, investigations aiming at developing new therapeutically important inhibitors have to be based on a combination of computational and experimental approaches including biochemical, cell-based or in silico screening and the study of the three-dimensional structure of the kinase active center, in complex with an inhibitor, using crystallography and X-ray analysis or molecular modeling. This work is an example of a combination of inhibitor experimental search with the computational analysis of the potential mechanism of the inhibitors’ action, which allowed to propose the 2-hydroxyphenol group as a scaffold for the design of new tyrosine kinase inhibitors.

protein tyrosine kinasessmall molecule inhibitorsscreening2-hydroxyphenol groupCohen P. // Nat. Rev. Drug Discov. 2002. V.1. P. 309–315.Gunby R.H., Sala E., Tartari C.J., Puttini M., Gambacorti-Passerini C., Mologni L. // Anti-Cancer Agents in Med. Chem. 2007. V.7. P. 594–611.Cohen M.H., Johnson J.R., Pazdur R. // Clin. Cancer Res. 2005. V. 11 (1). P. 12–9.Jianming Z., Priscilla L., Gray N.S. // Nat. Rev. Cancer. 2009. V. 9. P. 28–39.Hofmann W.-K., Jones L.C., Lemp N.A., de Vos S., Gschaidmeier H., Hoelzer D., Ottmann O.G., Koeffler H.P. // Blood. 2002. V. 99. P. 1860–1862.Bain J., Plater L., Elliott M., Shpiro N., Hastie J., McLauchlan H., Klevernic I., Arthur S.C., Alessi D., Cohen P. // Biochem. J. 2007. V. 408. P. 297–315.Faivre S., Djellou S., Raymond E. // Semin. Oncol. 2006. V. 33 (4). P. 407–420.Drews J. // Science. 2000. V. 287. P. 1960–1964.Anderson A. // Chem. - Biol. 2003. V. 10. P. 787–797.Chambers S.P., Austen D.A., Fulghum J.R., Kim W.M. // Protein Expr. Purif. 2004. V.36. P. 40–47.Mologni L., Sala E., Riva B., Cesaro L., Cazzaniga S., Redaelli S., Marin O., Pasquato N., Donella-Deana A., Gambacorti-Passerini C. // Protein Expr. Purif. 2005. V. 41. P. 177–185.Koresawa M., Okabe T. // Assay and Drug Dev. Technol. 2004. V. 2. P. 153–160.Zhang J.H., Chung T.D., Oldenburg K.R. // J. Biomol. Screen. 1999, V.4, P. 67–73.Fabbro D., Ruetz S., Buchdunger E., Cowan-Jacob S.W., Fendrich G., Liebetanz J., Mestan J., O’Reilly T., Traxler P., Chaudhuri B., Fretz H., Zimmermann J., Meyer T., Caravatti G., Furet P., Manley P.W. // Pharmacol Ther. 2002. V. 93 (2–3). P. 79–98.Stroganov O.V., Novikov F.N., Stroylov V.S., Kulkov V., Chilov G.G. // J. Chem. Inf. Model. 2008. V. 48. Р. 2371–2385.Walker E.H., Pacold M.E., Perisic O., Stephens L., Hawkins P.T., Whymann M.P., Williams R.L. // Mol. Cell. 2000. V. 6. P. 909–919.